CONTEXT
The vital prognosis of intestinal ischemia (sharp increase in blood flow towards the digestive tract) largely depends on its rapid diagnosis (mortality rate from 60% to 80%). We have recently identified a natural hormone that significantly increases in patients suffering from intestinal ischemia. This discovery allowed the qualification of this hormone as an early biomarker of intestinal ischemia.
DESCRIPTION
The said marker presents the characteristics of an ideal biomarker: precocity, sensitivity, produced by the intestine and measurable in the bloodstream. Quantitative detection tests are already commercialized for research use only and could be extended to a new market: clinical diagnosis. A rapid and reliable prognosis of this pathology would allow a better management of patients with intestinal ischemia and would therefore increase their survival rate.
COMPETITIVE ADVANTAGES
MARKETS & APPLICATIONS
Health - diagnosis :
DEVELOPMENT STAGE
Clinical results : increased biomarker plasma levels were observed in a preclinical mouse model with intestinal ischemia - increased levels of said biomarker were also seen after generating experimentally intestinal ischemia in human
RESEARCH TEAM
Laboratory Lipids, Nutrition, Cancer University of Burgundy - INSERM
INTELLECTUAL PROPERTY
French patent filed on Sept. 20th, 2016, & PCT Extension on March 28th, 2017 (national phases ongoing: EU, US, CN, JP, CA)
TARGET PARTNERSHIP
Patent licensing
CONTACT
Thomas BLUM
Business Developer
+33 (0)6 17 06 68 07
thomas.blum@sayens.fr